Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimalarials for treating rheumatoid arthritis.

M E Suarez-Almazor1, E Belseck, B Shea

  • 1Health Services Research, Veterans Affairs Medical Center, Mailbox Station 152, 2002 Holcombe Blvd, Houston, Texas 77024, USA. mes@bcm.tmc.edu

The Cochrane Database of Systematic Reviews
|October 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.

Communications medicine·2026
Same author

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors.

Seminars in arthritis and rheumatism·2025
Same author

Early COVID-19 pandemic modeling: Three compartmental model case studies from Texas, USA.

Computing in science & engineering·2022
Same author

A Short Report Examining the Introduction of Routine Use of Patient-Reported Outcome Measures in a Mixed Oncology Population.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism·2021
Same author

<i>trips4health</i>: Protocol of a single-blinded randomised controlled trial incentivising adults to use public transport for physical activity gain.

Contemporary clinical trials communications·2020
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Hydroxychloroquine demonstrates moderate efficacy in treating rheumatoid arthritis (RA) with a favorable safety profile. This antimalarial drug showed significant improvements compared to placebo, with fewer withdrawals due to lack of efficacy.

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
  • Antimalarials are a class of drugs used in the management of RA.
  • Assessing the efficacy and safety of antimalarials in RA is crucial for treatment guidelines.

Purpose of the Study:

  • To evaluate the short-term effectiveness and toxicity of antimalarials for rheumatoid arthritis treatment.
  • To synthesize evidence from randomized controlled trials (RCTs) and controlled clinical trials (CCTs).

Main Methods:

  • A systematic search of multiple databases (Cochrane, Medline, Embase) and handsearching of reference lists was conducted up to August 2000.
  • Included RCTs and CCTs comparing antimalarials to placebo in RA patients.
  • Data abstraction and quality assessment were performed independently; pooled analysis used standardized mean differences and odds ratios.

Related Experiment Videos

Main Results:

  • Four trials involving 592 patients were analyzed, focusing on hydroxychloroquine versus placebo.
  • Hydroxychloroquine showed statistically significant benefits in various outcome measures, including joint counts, pain, global assessments, and erythrocyte sedimentation rate (ESR).
  • Withdrawals due to lack of efficacy were higher in the placebo group, with no significant difference in toxicity-related withdrawals.

Conclusions:

  • Hydroxychloroquine is an effective treatment option for rheumatoid arthritis.
  • The drug offers a moderate therapeutic effect with a low toxicity profile, making it a valuable consideration for RA management.